Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease
NCT07537088Phase 4Not yet recruiting
- Sponsor
- Yejishan Hospital of Wannan Medical College
- Start
- May 2026
- Primary completion
- Apr 2027
- Modality
- Fc-Fusion Proteins
01
Overview
A Phase 4 trial of dulaglutide in type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD), sponsored by Yejishan Hospital of Wannan Medical College. Planned start May 2026; status: not yet recruiting.
02
Drugs
dulaglutide
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT07537088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537088.